Data Sheet (Cat.No.T3834)

TargetMol

8-Epideoxyloganic acid

Chemical Properties



CAS No. : 88668-99-9

Formula: C16H24O9

Molecular Weight: 360.36

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	8-Epideoxyloganic acid possesses bioactivities of analgesia, homeostasis and anti-inflammatory. It has the potential to serve as anti-inflammatory agents during oxidative stress, the inhibition of ROS production, possibly through modulation of NOX activity and/or the radical scavenging effect, and beta2 integrin expression in leucocytes. 8-Epideoxyloganic acid (oral) shows weak antinociceptive activity.
Targets(IC50)	Immunology/Inflammation related,ROS
In vivo	8-Epideoxyloganic acid?exhibited anti-inflammatory activity.

Solubility Information

Solubility	DMSO: 125 mg/mL (346.88 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+90% Saline: 10 mg/mL (27.75 mM),Solution. 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (2.78 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.775 mL	13.875 mL	27.750 mL
5 mM	0.555 mL	2.775 mL	5.550 mL
10 mM	0.2775 mL	1.3875 mL	2.775 mL
50 mM	0.0555 mL	0.2775 mL	0.555 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

The inhibitory effect of phenylpropanoid glycosides and iridoid glucosides on free radical production and beta2 integrin expression in human leucocytes. J Pharm Pharmacol. 2006 Jan;58(1):129-35.